INITIAL-1Recruiting

Inotuzumab-ozogamicin (drug) for the treatment of acute lymphoblastic leukemia (ALL) in patients aged 56 and older

Gender
Women and men
Age
56 years and older
Trial type
Interventional
Line of therapy
First line
Phase
Phase II

What is this trial about?

is a type of blood cancer that progresses rapidly and requires intensive treatment. Significant progress has been made in treatment in recent years; however, these intensive treatment regimens are often not suitable for older patients. The INITIAL-1 study is investigating the efficacy and safety of inotuzumab ozogamicin without additional intensive chemotherapy in older ALL patients. Eligible participants include women and men who have a new diagnosis of ALL (>25% ) and who are not eligible for the standard intensive therapy due to their age (>75 years) or pre-existing conditions (starting at age 56).

Detailed description

Acute lymphoblastic leukemia (ALL) is a form of blood cancer characterized by the excessive production of abnormal white blood cells (blasts) in the bone marrow. These immature cells displace normal blood cells, which can lead to a variety of health problems, including infections, , and increased bleeding. ALL is common in children, but older adults can also be affected. The prognosis for older patients is often poorer than for younger patients. The standard treatment for older patients with ALL often consists of intensive chemotherapy; however, due to side effects and comorbidities, this treatment is not always suitable and often must be discontinued.

The goal of the INITIAL-1 study is to test the efficacy of inotuzumab ozogamicin. This is an antibody that is conjugated to a targeted chemotherapeutic agent (calicheamicin) () and is directed against a surface receptor (CD22) on the cells. Calicheamicin is a highly effective drug that destroys cancer cells. It is already approved for the treatment of ALL in certain situations. All patients receive the same treatment (a single ) and are aware of it (open-label). As with all ALL patients, they will first receive pretreatment to prevent side effects; however, no standard chemotherapy is administered before the start of the study. This is followed by three of inotuzumab ozogamicin and a single intrathecal administration. Intrathecal therapy involves the direct treatment of the central nervous system; for this, the medication is injected with a needle into the cerebrospinal fluid space at the base of the spinal canal, which is technically equivalent to a lumbar puncture. Conventional are then used to maintain the treatment’s success (maintenance therapy). The study primarily evaluates after one year; this is the time without a disease-related event (e.g., of blasts in the bone marrow).

Eligible participants are patients who are at least 56 years old and have a new diagnosis of acute lymphoblastic leukemia with a blast count of > 25% in the bone marrow. Patients must not have received any prior specific ALL therapy, and they must be ineligible for conventional intensive therapy due to their age (> 75 years) or other medical conditions (in which case, age > 56 years). The CD22 receptor, which is specifically targeted by the study drug, must be present on at least 20% of the leukemia cells. The study will run for several years, during which patients will be monitored regularly for treatment response and any side effects.

Facts

  1. Disease: .
  2. Cancer characteristics: newly diagnosed, patients aged 56 years or older, CD22 expression ≥ 20%, cells > 25% in the bone marrow, not suitable for intensive standard chemotherapy, no prior treatment.
  3. What the study investigates: efficacy and safety of inotuzumab ozogamicin as for ALL (without intensive chemotherapy during induction).
  4. Study objective: To improve at 12 months in newly diagnosed older ALL patients.
  5. Study duration: 3 of treatment + followed by conventional chemotherapy as maintenance therapy, with for several years (at least 2 years).
  6. Study characteristics: Phase 2 study, single treatment arm, open-label (unblinded).

Trial sites

15 trial sites in Germany are listed. Find a site near you.

  • Universitätsklinikum Augsburg

    Sauerbruchstrasse 6, 86179 Augsburg

    Recruiting
  • Rheinische Friedrich-Wilhelms-Universitaet Bonn

    Venusberg-Campus 1, 53127 Bonn

    Recruiting
  • Klinikum Chemnitz gGmbH

    Chemnitz

    Recruiting
  • Universitätsklinikum Carl Gustav Carus Dresden

    Dresden

    Recruiting
  • Universitätsklinikum Düsseldorf

    40225 Düsseldorf

    Recruiting
  • Friedrich-Alexander-Universität Erlangen-Nürnberg

    Erlangen

    Recruiting

This list is compiled to the best of our knowledge but without guarantee: it may be incomplete, and a site's recruitment status can change at any time. Last checked against the trial registers on .

Medical editorial team

  • Dr. med. Sebastian SommerSpecialist in internal medicine with a focus on hematology and oncology
  • PD Dr. med. Matthias FröhlichSpecialist in internal medicine, immunology and emergency medicine

This description is based on the public trial registry entry and was translated into plain language by our medical editorial team. Whether participation is an option for you is a decision you make together with your treating physician.